CJC-1295 Without DAC + Ipamorelin: Two Signals, One Large Evidence Gap

Reviewed for accuracy by the Gorilla Research Insights research team · 2026-07-04

ENDOCRINE SIGNALING CJC-1295 Without DAC + Ipamorelin: Two Signals, One Large Evidence Gap This pairing combines a growth-hormone-releasing-hormone analogue with a ghrelin-receptor agonist. The mechanism is plausible; evidence for the exact combination is not the same thing.

Mechanistic frame

GHRH-receptor signaling and ghrelin-receptor signaling can each stimulate pituitary growth-hormone release through distinct receptor systems. Ipamorelin was characterized preclinically as a selective growth-hormone secretagogue ^[1]. That result does not establish outcomes for a combined research formulation. Published human trials of “CJC-1295” studied the long-acting drug-affinity-complex form, which prolonged growth-hormone and IGF-1 concentrations ^[2]. Those data should not be silently transferred to CJC-1295 without DAC: removing the albumin-binding modification changes pharmacokinetics, and the exact no-DAC-plus-ipamorelin mixture was not tested in that trial.

What the evidence supports

The literature supports a receptor-level rationale and demonstrates that related secretagogues can alter endocrine biomarkers. It does not establish improved recovery, body composition, sleep, longevity, or clinical benefit from this combination. Biomarker movement is not a substitute for a patient-centered endpoint.

Open questions

Key unknowns include the identity of the “no DAC” sequence sold under inconsistent names, combined pharmacokinetics, reproducibility of pulsatile responses, longer-term endocrine effects, and adverse-event frequency. Those questions require trials of the exact characterized material.

Primary sources

• ^[1] Raun et al. Ipamorelin, the first selective growth hormone secretagogue . • ^[2] Teichman et al. Randomized trials of long-acting CJC-1295 in healthy adults . Educational material only. It does not provide dosing or use advice.